Home / Oncology (page 30)

Oncology

Roche’ Cobas HPV Test Receives FDA Approval for First-line Cervical Cancer Screening

TUCSON, Ariz., July 30, 2018 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) approval for the cobas® HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using cervical specimens …

Read More »

Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab …

Read More »

Castle Biosciences’ DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer treatment decisions, today announced the presentation of new data showing that the DecisionDx®-Melanoma test improved risk prediction beyond that using American Joint Committee on Cancer (AJCC) based staging. The study was presented at the …

Read More »

BioLineRx Expands Immuno-Oncology Collaboration with Merck in Pancreatic Cancer

Tel Aviv, Israel, July 30, 2018 – BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the expansion of its immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) for the support of a Phase …

Read More »

Lilly and Dana-Farber Cancer Institute Extend Cancer Research Collaboration

INDIANAPOLIS, July 30, 2018 /PRNewswire/ — Eli Lilly and Company(NYSE: LLY) today announced a three-year extension of its cancer research collaboration with Dana-Farber Cancer Institute. Since 2015, scientists from Lilly and Dana-Farber have been working together on pre-clinical and clinical studies, molecular analyses of patient samples and the design and conduct of clinical trials to …

Read More »

Takeda’s Alunbrig Met Primary Endpoint Demonstrating Superior PFS Versus Crizotinib in Phase 3 Trial in Certain NSCLC Patients

CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the global, randomized, Phase 3 ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1st Line) trial met its primary endpoint at the first pre-specified interim analysis, with ALUNBRIG® (brigatinib) demonstrating a statistically significant improvement in progression-free survival (PFS) compared to crizotinib …

Read More »

Merck’s Keytruda Significantly Improved Overall Survival as First-Line Therapy in Head and Neck Squamous Cell Carcinoma in Phase 3 Study

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), met a primary endpoint of overall survival (OS) as …

Read More »

FDA Approves Magnetic Device System to Guide Sentinel Lymph Node Biopsies in Certain Breast Cancer Patients

The U.S. Food and Drug Administration today approved a magnetic device system for guiding lymph node biopsies in patients with breast cancer undergoing mastectomy. The Magtrace and Sentimag Magnetic Localization System (Sentimag System) uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel …

Read More »

Personal Genome Diagnostics’ PGDx elio Plasma Resolve Receives Breakthrough Device Designation from the FDA

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leading cancer genomics company and pioneer in liquid biopsy, today announced that PGDx elio™ plasma resolve has received Breakthrough Device designation from The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). PGDx elio™ plasma resolve is …

Read More »

Bristol-Myers Squibb and Tsinghua University Partner for Potential Therapies for Autoimmune Diseases and Cancer

BEIJING & NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Tsinghua University, have entered into a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers. The collaboration brings together Bristol-Myers Squibb and Tsinghua University’s respective scientific expertise and capabilities with a focus on validating new targets and generating …

Read More »